Litigation Details for Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D. Del. 2026)

Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D. Del. 2026)

Docket		Date Filed	2026-03-13
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Parties	CIPLA USA INC.
Patents	12,460,206
Attorneys	Daniel M. Silver
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D. Del. 2026)

Date Filed	Document No.	Description	Snippet	Link To Document
2026-03-13				External link to document

Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D.N.J.) | Case No. 1:26-cv-00272

Last updated: June 17, 2026

Executive summary. The action is a Hatch-Waxman patent infringement suit in the District of New Jersey brought by Novartis Pharmaceuticals Corporation against Cipla USA Inc. under case number 1:26-cv-00272. The complaint and docket events needed to produce a complete infringement-and-procedure analysis (asserted patents, Orange Book drug details, Paragraph IV theory, requested relief, claim construction posture, and current status) are not present in the provided material, so no accurate, citation-backed litigation summary can be generated.

What patents are asserted in Novartis v. Cipla USA Inc. 1:26-cv-00272?

Featured-snippet answer. Not determinable from the provided information.

Which patent numbers and claims does Novartis assert?

Not determinable. A litigation analysis requires the asserted patent list from the complaint (typically the “List of Patents” section and the infringement counts referencing specific claims).

Are patents for the active ingredient, formulation, or method-of-use asserted?

Not determinable. Hatch-Waxman complaints typically split asserted patents into drug substance, formulation, and/or method-of-use. That breakdown cannot be derived from the case caption alone.

What is the Orange Book hook for the infringement theory?

Not determinable. The Orange Book patent identifiers and listed reference product controls the scope of the infringement and any “use code” alignment for method-of-use patents.

What is the procedural posture in 1:26-cv-00272: motions to dismiss, TRO, injunction, or claim construction?

Featured-snippet answer. Not determinable from the provided information.

Is there a Paragraph IV notice and when was it served?

Not determinable. Timeline reconstruction depends on dates in the complaint, exhibits, and any reference to the FDA notice of certification.

Has the court issued any substantive rulings?

Not determinable. A true litigation posture requires docket entries (e.g., Rule 12 motions, venue/service rulings, Markman schedule, preliminary injunction briefing).

Has there been a stay under 30 months or another statutory trigger?

Not determinable. Hatch-Waxman stays depend on the date of patent certification and the “first filing” status for the first generic applicant.

When does exclusivity or patent expiration end for the Novartis reference drug in this suit?

Featured-snippet answer. Not determinable.

What is the earliest possible generic entry date if the patents are invalidated or not infringed?

Not determinable. This requires knowing: (i) the FDA approval date, (ii) pediatric exclusivity or 180-day exclusivity status, and (iii) the specific asserted patents’ expiration dates.

What is the likely “85/180/30-month” interaction for Cipla’s ANDA?

Not determinable. The calculation turns on ANDA filing date, Paragraph IV status, and who is the first Paragraph IV filer.

What FDA pathway and ANDA status underlies Novartis v. Cipla USA Inc.?

Featured-snippet answer. Not determinable.

Is Cipla’s product an ANDA, section 505(b)(2), or another regulatory pathway?

Not determinable from the case caption and number alone.

What dosage form and strength are at issue?

Not determinable. Litigation strategy and infringement analysis depend heavily on dosage form (tablet vs. capsule), strength, and release profile.

What is the infringement and invalidity framework in this case (literal infringement vs. doctrine of equivalents; §102/§103/§112)?

Featured-snippet answer. Not determinable.

How does Novartis allege infringement (direct, induced, contributory)?

Not determinable. The complaint must be reviewed for each asserted count.

What defenses does Cipla raise (noninfringement, invalidity grounds, §112 enablement/indefiniteness, inequitable conduct)?

Not determinable. The analysis requires the answer, any amended pleadings, and claim construction positions.

What claim construction issues are likely to matter in Novartis v. Cipla USA Inc. 1:26-cv-00272?

Featured-snippet answer. Not determinable.

What claim terms typically drive outcomes in similar Hatch-Waxman cases?

Not determinable for this specific matter. Term-by-term constructions require the actual asserted claims and claim language.

Has Cipla challenged the asserted patents via Paragraph IV invalidity theories or another certification mechanism?

Featured-snippet answer. Not determinable.

What is the certification baseline (invalid/not infringed vs. no claim to the use code)?

Not determinable. Certification type and “use code” mapping require the Orange Book and complaint details.

What settlement or standstill agreements exist (if any) in 1:26-cv-00272?

Featured-snippet answer. Not determinable.

Is there a consent judgment, dismissal without prejudice, or phased dismissal?

Not determinable. These events require docket entries.

How strong is the Novartis patent estate in this dispute versus Cipla’s generic entry risk?

Featured-snippet answer. Not determinable.

What is the asserted-patent “survival profile” (known litigations, PTAB/other challenges, prosecution history)?

Not determinable. Strength metrics require the patents, inventors/assignees, and any known prior proceedings.

What is the likely scope of design-around or formulation workarounds?

Not determinable. This depends on whether formulation/process/method claims are asserted.

Which courts and judges are involved, and what does that imply for pacing or typical claim construction?

Featured-snippet answer. Not determinable from the provided information.

What is the assigned judge and scheduling order status?

Not determinable. Docket metadata is required.

Key takeaways

• The case number alone (1:26-cv-00272) does not contain the infringement, regulatory, or procedural facts required for a litigation summary.
• A correct litigation analysis requires the complaint’s asserted-patent list, ANDA reference-product mapping, certification theory, and current docket posture.
• No accurate, actionable conclusions on infringement strength, exclusivity timelines, or generic entry risk can be provided from the provided information.

FAQs

1. What is a Hatch-Waxman patent infringement complaint’s minimum information required to analyze Paragraph IV claims?
   Asserted patent numbers and claims, reference product and Orange Book identifiers, ANDA details, certification basis, and requested remedies.

2. How do 30-month stays interact with first-filer 180-day exclusivity in generic cases?
   The interaction depends on the first Paragraph IV filer designation, ANDA filing dates, and whether the litigation was brought within statutory deadlines.

3. What documents usually reveal the asserted patent list in a patent case?
   The infringement complaint and any exhibit listing the patents and certification codes.

4. How do settlements usually change the practical timeline for generic launch?
   Settlements often include dismissal terms, launch triggers, and payment-for-delay restrictions under antitrust scrutiny.

5. What drives claim construction outcomes in formulation versus method-of-use patents?
   Formulation claims often hinge on measurable composition parameters; method-of-use claims hinge on whether the accused labeling and use instructions map to the claimed steps.

References

1. United States District Court for the District of New Jersey. Novartis Pharmaceuticals Corporation v. Cipla USA Inc., Case No. 1:26-cv-00272.